INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study.

Purpose:To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in patients with refractory posterior uveitis in Behcet's disease.Methods:Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0–4), vasculitis, retinitis, and papil